Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses.
ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation.
"Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025."
The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on clinicaltrials.gov.
ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity.
About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit www.metabolicspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625436712/en/
Contacts
Company contact: Richard Larson, M.D., Ph.D.Chief Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial Officerj.dessouki@metabolicspharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
15 minutes ago
- Los Angeles Times
New Report on State of Technology in Value-Based Care Exposes Tech and Data Barriers
Glendale-based Reveleer, a leading value-based care technology platform, in partnership with Mathematica, a policy data and analytics company, has released the '2025 State of Technology in Value-Based Care Report.' The report comes during a pivotal moment in healthcare transformation. While payer and provider alignment around value-based care (VBC) has never been stronger, execution is falling behind. The report reveals that while there is widespread confidence in technology's potential to support value-based care, significant barriers such as fragmented data strategies, uneven AI adoption and insufficient staff training are hindering progress and scalability. The report findings defy a common industry narrative that payers and providers are misaligned on priorities. In fact, 100% of providers and 97% of payers surveyed agree their value-based care goals are strongly aligned. What's missing is synchronized execution. Despite shared vision, payers and providers are operating in parallel rather than in concert, pointing to an inefficiency that limits the impact of technology investments and makes scale more difficult. Meanwhile, momentum continues to build: 92% of payers and 81% of providers surveyed saw their VBC contracts grow in the past 12 months. And even more expect growth ahead, with 94% of payers and 83% of providers forecasting increases in the next 12 months. But if execution continues to lag behind ambition, progress may stall before it can transform care. 'To realize the full potential of value-based care, payers and providers must collaborate at scale,' said Jay Ackerman, CEO of Reveleer. 'The good news is payers and providers are finally rowing in the same direction. But if they don't row in sync, we won't move forward. This report points to a clear call to action. The alignment is there, and the tools are ready. Tighter collaboration and true transformation are within reach.' Data management is viewed as a strategic asset by virtually every organization surveyed. 97% of providers and 96% of payers agree that a strong data management approach gives them a competitive edge in the marketplace. Yet behind that confidence lies significant operational fragmentation. Only a third of surveyed providers (33%) and payers (31%) rate their data integration capabilities as 'excellent.' Yet only about half (46% of providers and 53% of payers) are very confident in the accuracy and completeness of the patient data they use in VBC initiatives. This gap between perception and precision signals a major vulnerability in scaling VBC effectively and safely. Every payer and provider surveyed reports using AI. And most agree it's delivering results: 96% of both payers and providers agree their approach to AI adoption and implementation has given them a competitive advantage, and more than 80% of each report seeing positive impacts, including: But enthusiasm hasn't translated into full commitment. Only 40% of payers and 38% of providers say they are fully committed to AI adoption. Just 21% of payers and 29% of providers report a significant increase in AI use in the past 12 months. Underlying this hesitation are concerns about AI hallucinations, algorithmic transparency and the ethics of AI-assisted decisions without human oversight. These concerns don't negate AI's value, but they do signal the need for more robust frameworks for responsible adoption. Despite confidence in AI's promise, organizations are underinvesting in the people who need to use it. While all organizations surveyed offer at least some AI training, only 30% of payers and 32% of provider organizations offer extensive training programs. This lack of preparation is a likely contributor to AI hesitancy and a barrier to scaling its use. As the pressure to improve outcomes and reduce costs intensifies, organizations that pair technology with workforce readiness will be better positioned to lead. 'Technology is a powerful enabler, but it's not a magic wand,' said Ngan MacDonald, director of data innovations at Mathematica. 'The path to scalable value-based care demands more than alignment. It demands real investment in data infrastructure, workforce readiness and AI governance. This report highlights where the friction lies and where leaders need to focus next.' Information sourced from Reveleer. To learn more, contact srubin@
Business Wire
15 minutes ago
- Business Wire
New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled 'A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis' Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the Company's corporate website. 'IMPALA-2, the largest and longest Phase 3 clinical trial conducted in patients with autoimmune PAP, demonstrated that 48 weeks of once daily administration of inhaled molgramostim addresses the underlying pathophysiology of this chronic rare lung disease,' said Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine and Lead Clinical Investigator of the IMPALA-2 trial. 'Treatment with molgramostim improved the cardinal manifestations of autoimmune PAP, namely it reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. Additionally, molgramostim was well tolerated with no notable safety concerns.' IMPALA-2 achieved statistical significance on its primary endpoint, change from baseline in the hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%) at Week 24. Molgramostim significantly improved pulmonary gas transfer as measured by DLco% at Week 24 compared with placebo (9.8% vs. 3.8%; estimated treatment difference, 6.0%; P<0.001 by comparison of least-squares means [LSMs]). The beneficial effect of molgramostim on pulmonary gas transfer was maintained to Week 48 as shown by the difference in LSM change from baseline in DLco% at Week 48 between molgramostim and placebo groups (11.6% vs. 4.7%; estimated treatment difference, 6.9%; P<0.001). The mean improvements in DLco% from baseline for molgramostim (9.8% at Week 24 and 11.6% at Week 48) are similar to the minimal clinically meaningful difference (MCID) in DLco% of 10% reported for pulmonary fibrosis. 1 Molgramostim improved respiratory health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) Total and Activity scores. The magnitude of LSM reduction from baseline in SGRQ Total score was significantly greater in the molgramostim group than placebo at Week 24 (-11.5 points vs. -4.9 points, estimated difference, -6.6 points; P=0.007) and remained numerically greater at Week 48 (-10.7 points vs. -5.9 points, estimated difference, -4.9 points [95% confidence interval, -10.8, 1.0]). The LSM change from baseline in SGRQ Activity score was greater for molgramostim compared with placebo at Week 24 (-13.0 points vs. -5.2 points, estimated difference, -7.8 points [95% confidence interval, -14.1, -1.5]) and at Week 48 (-13.4 vs. -7.4 points, estimated difference, -6.0 points [95% confidence interval, -13.6, 1.6]). Molgramostim improved patient function as measured by exercise capacity (expressed as peak metabolic equivalents [METs]). A MET is a unit of resting oxygen uptake which measures energy expenditure. The LSM change from baseline in peak-METs was greater at Week 48 for molgramostim than placebo (1.1 vs. 0.6; estimated treatment difference, 0.6; [95% confidence interval, 0.1, 1.0]). Peak-METs is a clinically useful unit of measure reflecting exercise capacity, prognosis, and mortality in cardiovascular disease for which a 0.5-MET increase comprises a clinically useful measure of rehabilitation. 2 Using the treadmill test in IMPALA-2, the LSM change in peak-METs from baseline to Week 48 was 1.1 in molgramostim-treated patients and the between-group difference observed at Week 48 was 0.6 peak-METs. Molgramostim reduced surfactant burden as measured by ground glass opacity (GGO) score, an exploratory endpoint in IMPALA-2; GGO scores were determined by two blinded radiologists from a chest CT scan, with scores ranging from 0 to 15 (higher scores are worse). The mean reduction from baseline in GGO score was greater in the molgramostim group than the placebo group at Week 24 (-2.1 vs -1.1). Further, the number of patients who received ≥1 whole lung lavage as rescue therapy during the double-blind intervention period was lower with molgramostim than placebo (6 [7%] vs. 11 [13%]). In IMPALA-2, molgramostim was well tolerated. Most treatment-emergent adverse events (AEs) were mild or moderate, and few led to discontinuation, with 98% of patients in the molgramostim group and 96% of patients in the placebo group completing the 48-week double-blind period on treatment. About IMPALA-2 IMPALA-2 was a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once daily by inhalation with matching placebo in patients with autoimmune PAP. The trial was conducted at 43 clinical trial sites across 16 countries, including the U.S., Canada, Japan, South Korea, Australia, and countries in Europe, including Turkey. The primary efficacy assessment was hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%), a gas transfer measure, and the primary endpoint was change from baseline to Week 24 in percent predicted DLco%, with a secondary endpoint of change from baseline to Week 48 in percent predicted DLco%. Three additional secondary efficacy variables evaluated clinical measures of patient benefit: St. George's Respiratory Questionnaire (SGRQ) Total score, SGRQ Activity score, and exercise capacity using a treadmill test, with each endpoint measured at Weeks 24 and 48. The primary time point for efficacy assessments was at Week 24; however, efficacy was assessed through Week 48 to evaluate durability of effect. Safety was assessed through Week 48. All patients who completed the 48-week double-blind treatment period continued into a 96-week open-label period during which molgramostim 300 mcg is administered once daily. Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. 1 Raghu G, et al. Am J Respir Crit Care Med 2022;205:e18-e47. 2 Ross R, et al. Circulation 2016;134:e653-e99; Grace SL, et al. Can J Cardiol 2014;30:945-8; Kehler DS, et al. J Cardiopulm Rehabil Prev 2017;37:250-6.
USA Today
an hour ago
- USA Today
New 'tiny' moon found orbiting Uranus, bringing satellite family to 29
A team at the NASA has discovered a new moon orbiting Uranus, and this one is even smaller than the others. A team led by the Southwest Research Institute (SwRI) discovered the moon on Feb. 2. They made the discovery using NASA's James Webb Space Telescope, which the space agency says is the largest, most powerful telescope ever launched into space. The newly-discovered moon, called S/2025 U1, is about 6 miles in diameter, NASA said, calling it "tiny." Its discovery brings Uranus' total satellite family to 29. "This object was spotted in a series of 10 40-minute long-exposure images captured by the Near-Infrared Camera (NIRCam)," said Maryame El Moutamid, a Colorado-based lead scientist from SwRI, in a news release. "It's a small moon but a significant discovery, which is something that even NASA's Voyager 2 spacecraft didn't see during its flyby nearly 40 years ago." According to NASA, the NIRCam used to detect the new moon has high resolution and infrared sensitivity that allows it to pick up faint, distant objects. Where is the new 'tiny' moon? Uranus is the seventh planet from the sun, and the third-largest planet in our solar system, according to NASA. It is a cold, windy planet that is surrounded by faint rings. The planet differs from the others because it has more small inner moons, Matthew Tiscareno, who is on the research team that discovered the moon, said in the news release. "The new moon is smaller and much fainter than the smallest of the previously known inner moons, making it likely that even more complexity remains to be discovered," Tiscareno said. The new moon, Moon S/2025 U1, is located about 35,000 miles from Uranus' center, between the orbits of Ophelia and Bianca. It is the 14th small moon orbiting inward of these larger moons, NASA said. While Uranus now has a total of 29 moons, NASA said five of them are considered major moons: Miranda, Ariel, Umbriel, Titania and Oberon. Moons on Uranus are often called the literary moons because they are named after Shakespearean characters, as well as characters from titles by the English author Alexander Pope. Before the new moon gets an official name of its own, the International Astronomical Union (IAU) will need to approve it, according to the news release. The union is responsible for officiating names and designations for astronomical objects. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@
